Adam Bress, PharmD, MS, will present “Intensive Blood Pressure Control: What We Have Learned, What Comes Next, and What Longitudinal Plasma Biomarkers in SPRINT Might Tell Us About Interactions with Alzheimer’s Pathology and Dementia Risk," an in-depth examination of the evidence behind intensive blood pressure control, highlighting lessons from SPRINT and emerging data on longitudinal plasma biomarkers. The seminar will explore cardiovascular and cognitive outcomes, unanswered questions in hypertension management, and how biomarker research may clarify interactions between antihypertensive therapy, Alzheimer’s pathology, and dementia risk.

Dr. Bress is Professor of Population Health Sciences at the University of Utah School of Medicine, Director of the IMPACT Health Services Research Program, and an Investigator at the VA Salt Lake City Health Care System. A cardiovascular clinical pharmacist and population health scientist, his research integrates pharmacoepidemiology, causal inference, health economics, and predictive modeling to improve medication use for cardiovascular and neurodegenerative disease prevention. He leads a long-standing NIH-funded research program and is MPI of a $21 million NIH award generating the first longitudinal biomarker data on cognitive effects of intensive blood pressure control by baseline Alzheimer’s pathology. His work has informed national hypertension guidelines and federal research priorities.

Dr. Bress is visiting Pitt as a CP3 and Pitt Pharmacy–sponsored Visiting Scholar.